SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Edward W. Richmond who wrote (1141)12/21/2000 9:22:43 PM
From: Ian@SI  Respond to of 1321
 
Ed,

Thanks for the specialist feedback.

I do hope that your vision recovers fully and quickly.
I agree that QLT's outlook, and that of Visudyne, remain very positive. As the reimbursement issues get put to bed; and as the label gets broadened [is that a verb?], the revenue growth should accelerate very nicely.

I still have no chance to sell at, or anywhere near $100/share. And I can be as patient as the market forces me to be. I have another 12 years before I plan to take any money out of equities.

Happy holidays and best wishes to you and family,
Ian.



To: Edward W. Richmond who wrote (1141)12/21/2000 9:46:43 PM
From: Scripts  Read Replies (1) | Respond to of 1321
 
Hi Ed:

This thing is looking grim to me too. A cure for blindness and the price drops like a stone. The best interpretation I can see is that the drop makes no sense logically and the longer term situation will unfold when the next earnings are reported. If they are OK so are we--if not we are in trouble big time long time.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News